Infliximab SC Medicine 12 June 2018 Extended indication Rheumatoid Arthritis Therapeutic value No judgement Total cost Registration phase Clinical trials Product Active substance Infliximab SC Domain Chronic immune diseases Reason of inclusion Main indication Rheumatism Extended indication Rheumatoid Arthritis Current proprietary name Already available biosimilars / generics Proprietary name CT-P13 SC Manufacturer Celltrion Portfolio holder Mechanism of action Unknown Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Nieuwe toedieningsvorm van CT-P13 IV Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity New therapeutical formulation ATMP Unknown Submission date Expected Registration 2019 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks http://www.theinvestor.co.kr/view.php?ud=20170607000658 Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT03147248 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks